Insider Selling: Solid Biosciences Inc (NASDAQ:SLDB) CEO Sells 11,124 Shares of Stock

Solid Biosciences Inc (NASDAQ:SLDB) CEO Ilan Ganot sold 11,124 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $2.42, for a total value of $26,920.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of NASDAQ:SLDB opened at $2.63 on Friday. The business’s fifty day moving average price is $2.98 and its two-hundred day moving average price is $2.97. The stock has a market cap of $120.70 million, a PE ratio of -0.99 and a beta of 1.26. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.50 and a current ratio of 4.50. Solid Biosciences Inc has a one year low of $1.96 and a one year high of $13.58.

Solid Biosciences (NASDAQ:SLDB) last announced its earnings results on Thursday, May 7th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.08. As a group, equities research analysts predict that Solid Biosciences Inc will post -1.67 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in SLDB. Credit Suisse AG grew its holdings in Solid Biosciences by 37.2% during the 4th quarter. Credit Suisse AG now owns 15,091 shares of the company’s stock valued at $67,000 after buying an additional 4,090 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Solid Biosciences by 79.7% during the fourth quarter. Renaissance Technologies LLC now owns 58,040 shares of the company’s stock worth $258,000 after purchasing an additional 25,740 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Solid Biosciences by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 73,008 shares of the company’s stock worth $324,000 after purchasing an additional 3,724 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Solid Biosciences by 19.8% during the fourth quarter. Geode Capital Management LLC now owns 275,214 shares of the company’s stock worth $1,224,000 after purchasing an additional 45,465 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Solid Biosciences during the first quarter worth $120,000. Hedge funds and other institutional investors own 57.28% of the company’s stock.

A number of analysts have weighed in on the company. SVB Leerink cut Solid Biosciences from an “outperform” rating to a “market perform” rating and set a $3.00 price objective for the company. in a research report on Monday, July 27th. Chardan Capital reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Solid Biosciences in a research note on Saturday, May 9th. Finally, Nomura reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Solid Biosciences in a research note on Thursday, May 21st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. Solid Biosciences has a consensus rating of “Hold” and a consensus price target of $7.38.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

Further Reading: Trading based on a resistance level

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.